PMID- 24940504
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 2
IP  - 4
DP  - 2014 Jul
TI  - Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients 
      undergoing dose reduction and those with a low body surface area.
PG  - 604-608
AB  - The objective of this study was to evaluate the efficacy of epidermal growth 
      factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patients undergoing 
      dose reduction and in those with a low body surface area (BSA). The association 
      between dose reduction, low BSA and efficacy, including response rate (RR), 
      disease control rate (DCR), progression-free survival (PFS) and overall survival 
      (OS), were evaluated in patients prescribed TKIs between September, 2002 and May, 
      2013. A total of 282 patients received EGFR-TKIs during the study period, 53 
      (18.8%) of whom underwent a dose reduction (21.4 and 31.6% of the patients with a 
      BSA of <1.5 and <1.25 m(2), respectively). Eleven (20.8%) of these 53 patients 
      had a dose reduction due to adverse events (AEs) >grade 3. In either gefitinib or 
      erlotinib treatment, the RR, DCR, PFS and OS in EGFR-mutated patients with a BSA 
      of <1.5 m(2) were not different from those in patients with a BSA of >1.5 m(2). 
      In addition, there were no differences in these parameters between patients with 
      and those without a dose reduction of TKIs. The dose of TKIs in patients with AEs 
      and in those with low BSA should be determined with caution. To confirm the equal 
      efficacy of TKIs in patients undergoing a dose reduction, prospective 
      observational studies with less patient heterogeneity are required.
FAU - Sato, Shinya
AU  - Sato S
AD  - Division of Respiratory Medicine, Ryugasaki Saiseikai General Hospital, 
      Ryugasaki, Ibaraki 301-0854, Japan.
FAU - Kurishima, Koichi
AU  - Kurishima K
AD  - Division of Respiratory Medicine, Faculty of Clinical Medicine, University of 
      Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
FAU - Miyazaki, Kunihiko
AU  - Miyazaki K
AD  - Division of Respiratory Medicine, Ryugasaki Saiseikai General Hospital, 
      Ryugasaki, Ibaraki 301-0854, Japan.
FAU - Kodama, Takahide
AU  - Kodama T
AD  - Division of Respiratory Medicine, Ryugasaki Saiseikai General Hospital, 
      Ryugasaki, Ibaraki 301-0854, Japan.
FAU - Ishikawa, Hiroichi
AU  - Ishikawa H
AD  - Division of Respiratory Medicine, Tsukuba Medical Center Hospital and Regional 
      Cancer Center, Tsukuba, Ibaraki 305-8558, Japan.
FAU - Kagohashi, Katsunori
AU  - Kagohashi K
AD  - Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, 
      Mito, Ibaraki 310-0015, Japan.
FAU - Tamura, Tomohiro
AU  - Tamura T
AD  - Division of Respiratory Medicine, Faculty of Clinical Medicine, University of 
      Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
FAU - Homma, Shinsuke
AU  - Homma S
AD  - Division of Respiratory Medicine, Faculty of Clinical Medicine, University of 
      Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
FAU - Satoh, Hiroaki
AU  - Satoh H
AD  - Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, 
      Mito, Ibaraki 310-0015, Japan.
FAU - Hizawa, Nobuyuki
AU  - Hizawa N
AD  - Division of Respiratory Medicine, Faculty of Clinical Medicine, University of 
      Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
LA  - eng
PT  - Journal Article
DEP - 20140416
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC4051560
OTO - NOTNLM
OT  - body surface area
OT  - dose reduction
OT  - epidermal growth factor receptor-tyrosine kinase inhibitor
OT  - erlotinib
OT  - gefitinib
OT  - non-small-cell lung cancer
EDAT- 2014/06/19 06:00
MHDA- 2014/06/19 06:01
PMCR- 2014/04/16
CRDT- 2014/06/19 06:00
PHST- 2014/01/27 00:00 [received]
PHST- 2014/04/08 00:00 [accepted]
PHST- 2014/06/19 06:00 [entrez]
PHST- 2014/06/19 06:00 [pubmed]
PHST- 2014/06/19 06:01 [medline]
PHST- 2014/04/16 00:00 [pmc-release]
AID - mco-02-04-0604 [pii]
AID - 10.3892/mco.2014.281 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2014 Jul;2(4):604-608. doi: 10.3892/mco.2014.281. Epub 2014 Apr 
      16.